Jon Cousin

Associate
Full contact info

Passions

Skiing

Fly-fishing

Staying active

Spending time with family

Experience

Secura Bio Acquires Global Rights to Farydak

November 15, 2022

Cooley advised Secura Bio on intellectual property diligence matters surrounding its acquisition of global rights to Farydak from Novartis. Farydak is a prescription medication used to treat patients who have received prior treatment for multiple myeloma, a cancer that forms malignant plasma cells in the bone marrow.

“We are very pleased to acquire worldwide rights to Farydak as we execute our plan to aggressively build a meaningful, worldwide oncology portfolio,” said Joseph M. Limber, president and CEO at Secura Bio. “Farydak will be a critical cornerstone of our strategy, as it offers a potentially valuable and high-growth treatment option for physicians in their therapeutic regimen for multiple myeloma patients when combined with a variety of other multiple myeloma therapies.”

Related contacts

Jon Cousin
Associate, Washington DC

Related Practices & Industries

Secura Bio Acquires Global Rights to Copiktra

November 15, 2022

Cooley advised Secura Bio on intellectual property diligence matters surrounding its $311 million acquisition ($70 million upfront and $241 million in milestones) of global rights to Copiktra. Copiktra is a prescription oncology medication used to treat patients who have received prior treatment for certain types of cancer, such as chronic lymphocytic leukemia and small lymphocytic lymphoma.

“Completing the Copiktra acquisition represents a major step in building our worldwide oncology portfolio,” said Joseph M. Limber, president and CEO at Secura Bio.

 

Related contacts

Jon Cousin
Associate, Washington DC

Related Practices & Industries

Sixth Street Invests in Blueprint Medicines

July 7, 2022

Cooley advised global investment firm Sixth Street on its strategic investment in Blueprint Medicines, a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Lawyers Mischi a Marca, Matt Browne, Matt Scarano, Addison Pierce, Matt Kong and Nick Neuteufel led the Cooley team advising Sixth Street. 

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Matt Browne
Partner, San Diego
Matthew S. Scarano
Associate, San Diego
Addison Pierce
Associate, Chicago
Matt Kong
Associate, San Francisco
Michael Tuscan
Partner, Washington DC
Jon Cousin
Associate, Washington DC
Tanya Heare-Rowlands
Special Counsel, London
Matthew Everhart
Patent Agent, Washington DC
Jeffery Wyzykowski
Patent Agent, Washington DC
Matthew Scheideman
Patent Agent, Washington DC
Charity Williams
Partner, San Diego
Freddy Yip
Associate, Hong Kong
Zack Gong
Associate, Shanghai
Natasha Leskovsek
Of Counsel, Washington DC
Phil Mitchell
Partner, New York
Jennifer Shanley
Special Counsel, New York
Elizabeth Anne Wright
Partner, Brussels
Aaron Pomeroy
Partner, Colorado
Michael Klein
Partner, New York
Paul Springer
Associate, New York
Megan Browdie
Partner, Washington DC
Howard Morse
Partner, Washington DC

Related Practices & Industries

Rodeo Therapeutics Agrees to Sell to Amgen for $721 Million

March 31, 2021

Cooley advised Rodeo Therapeutics, a biopharmaceutical company that develops small molecule therapies, on its agreement to sell to Amgen, a leader in biotechnology-based human therapeutics, for $721 million. Partner Laura Medina led the Cooley team advising Rodeo. 

Read more

Related contacts

Meredith Klionsky
Associate, Washington DC
Laura M. Medina
Partner, Colorado
Ajay Athavale
Associate, San Francisco
Willy Cowles
Associate, Seattle
Alexander Ellebracht
Associate, Palo Alto
Charity Williams
Partner, San Diego
Yuri Weigel
Special Counsel, Seattle
Sonya Erickson
Partner and Business Department Chair, Seattle
Jon Cousin
Associate, Washington DC
Patrick Sharma
Associate, Los Angeles Santa Monica
Mark Windfeld-Hansen
Senior Counsel, Palo Alto

Related Practices & Industries

Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million

July 11, 2019

Jazz Pharmaceuticals in its acquisition of Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz. Jazz will be responsible for further development, regulatory activities and commercialization. Jazz will pay Redx an upfront payment of $3.5 million. Redx is eligible to receive up to $203 million in development, regulatory and commercial milestone payments and incremental tiered royalties in mid-single digit percentage, based on any future net sales.

Related contacts

Marya Postner
Partner, Palo Alto
Geoffrey Spolyar
Partner, Boston
John Clark
Partner, London
John Wilkinson
Partner, London
Barbara Borden
Partner, San Diego
Jon Cousin
Associate, Washington DC
Shehzad Akram
Trainee Solicitor , London
Rachel Thorn
Partner, New York

Related Practices & Industries

View more

Memberships & affiliations

American Intellectual Property Law Association